Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 134

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 134
---
 and training for the use
of Spryng®, we believe its successful commercialization will depend on other material factors including our ability to
educate and convince veterinarians and pet owners about the benefits, safety and effectiveness of Spryng®, the occurrence
and severity of any side effects to pets from use of our products, maintaining regulatory compliance and effective quality control for
our products, our ability to maintain and enforce our patents and other intellectual property rights, any increased manufacturing costs
from third-party contractors or suppliers, and the availability, cost and effectiveness of treatments offered by competitors.

Our
lead product, Spryng®, will face significant competition in our industry, and our failure to compete effectively may prevent
us from achieving any significant market penetration.

The
development and commercialization of animal care products is highly competitive, including significant competition from major pharmaceutical,
biotechnology, and specialty animal health medical companies. Our competitors include Zoetis, Inc.; Merck Animal Health, the animal health
division of Merck & Co., Inc.; Merial, the animal health division of Sanofi, S.A.; Elanco, the animal health division of Eli Lilly
and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis
AG; Boehringer Ingelheim Animal Health; Virbac Group; Ceva Animal Health; Vetaquinol; and Dechra Pharmaceuticals PLC. There also are
several smaller stage animal health companies that have recently emerged in our industry and are developing therapeutics products that
may compete with Spryng®, including Kindred Bio, Aratana Therapeutics, Next Vet, and VetDC.

15

Since
we are an early-stage company with limited operations and financing, virtually all our competitors have substantially more financial,
technical and personnel resources than us. Most of them also have established brands and substantial experience in the development, production,
regulation, and commercialization of animal health care products. Regarding our development of any new products or technology, we also
compete with academic institutions, governmental agencies and private organizations that conduct research in the field of animal health
medicines. We expect that competition in our industry is based on several factors including primarily product reliability and effectiveness,
product pricing, product branding, adequate patent and other IP protection, safety of use, and product availability.

Although
for the foreseeable future, our efforts and financial resources will continue to focus on successfully commercializing Spryng®, our
future